Technology access partnership to advance NDD research

Drug discovery startup Neurolentech, focused on epilepsy and related genetic neurodevelopmental disorders (NDDs), has formed an agreement enabling Kaerus Bioscience to access its NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens, to drive advances in this field of research.

A spin out from IST Austria, Neurolentech's Platform comprises a vast collection of human-derived neuronal cell lines from patients with monogenic and complex neurodevelopmental disorders. Kaerus Bioscience will be using the platform to model the complex neural networks underlying clinical features of genetic NDDs at a cellular level, as well as to investigate the therapeutic potential of its small molecule pipeline for numerous genetic syndromes preclinically.

Fiona Nielsen, CEO of Neurolentech, said, “We are excited to collaborate with Kaerus Bioscience in advancing their programs in the field of neurodevelopmental disorders. Our platform's unique capabilities offer unparalleled insights into disease mechanisms, facilitating the development of novel therapies."

Robert Ring, CEO of Kaerus Bioscience, added, "Our partnership with Neurolentech underscores Kaerus’ commitment to leveraging cutting-edge technology and innovative platform approaches to accelerating the discovery of treatments for patients with genetic disorders of neurodevelopment.”

More information online